These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. Sivakumar T; Mechanic O; Fehmie DA; Paul B HIV Med; 2011 Sep; 12(8):453-62. PubMed ID: 21265979 [TBL] [Abstract][Full Text] [Related]
3. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H AIDS; 2002 Nov; 16(16):2183-93. PubMed ID: 12409740 [TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones in the treatment of HIV/HAART-associated lipodystrophy syndrome. Edgeworth A; Treacy MP; Hurst TP AIDS Rev; 2013; 15(3):171-80. PubMed ID: 24002201 [TBL] [Abstract][Full Text] [Related]
5. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy. Sutinen J; Kannisto K; Korsheninnikova E; Fisher RM; Ehrenborg E; Nyman T; Virkamäki A; Funahashi T; Matsuzawa Y; Vidal H; Hamsten A; Yki-Järvinen H Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E941-9. PubMed ID: 14749206 [TBL] [Abstract][Full Text] [Related]
6. Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment. Magkos F; Mantzoros CS Metabolism; 2011 Jun; 60(6):749-53. PubMed ID: 20965525 [No Abstract] [Full Text] [Related]
7. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. Jones SP; Qazi N; Morelese J; Lebrecht D; Sutinen J; Yki-Jărvinen H; Back DJ; Pirmohamed M; Gazzard BG; Walker UA; Moyle GJ J Acquir Immune Defic Syndr; 2005 Dec; 40(5):565-72. PubMed ID: 16284533 [TBL] [Abstract][Full Text] [Related]
8. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients]. Leclercq P; Blanc M Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979 [TBL] [Abstract][Full Text] [Related]
9. [Criteria for AIDS-prices 2003. Why does HAART therapy in HIV patients cause fat catabolism?]. Urologe A; 2003 Sep; 42(9):1254. PubMed ID: 14619845 [No Abstract] [Full Text] [Related]
10. Management of the metabolic effects of HIV and HIV drugs. Brown TT; Glesby MJ Nat Rev Endocrinol; 2011 Sep; 8(1):11-21. PubMed ID: 21931374 [TBL] [Abstract][Full Text] [Related]
11. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Flint OP; Noor MA; Hruz PW; Hylemon PB; Yarasheski K; Kotler DP; Parker RA; Bellamine A Toxicol Pathol; 2009 Jan; 37(1):65-77. PubMed ID: 19171928 [TBL] [Abstract][Full Text] [Related]